David B. Roberts Sells 5,025 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director David B. Roberts sold 5,025 shares of the company’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $75.62, for a total value of $379,990.50. Following the sale, the director now directly owns 14,114 shares in the company, valued at $1,067,300.68. The sale was disclosed in a filing with the SEC, which is available through this link.

LeMaitre Vascular Price Performance

Shares of LMAT stock opened at $76.00 on Friday. The company has a market cap of $1.71 billion, a P/E ratio of 50.33, a PEG ratio of 2.99 and a beta of 0.88. The stock’s 50-day moving average is $66.67 and its 200 day moving average is $59.46. LeMaitre Vascular, Inc. has a 1-year low of $44.27 and a 1-year high of $76.24.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.05. The business had revenue of $53.48 million for the quarter, compared to the consensus estimate of $51.50 million. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The company’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.27 EPS. On average, analysts anticipate that LeMaitre Vascular, Inc. will post 1.77 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 30th. Investors of record on Thursday, May 16th will be issued a $0.16 dividend. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $0.64 annualized dividend and a yield of 0.84%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 42.38%.

Institutional Trading of LeMaitre Vascular

Institutional investors and hedge funds have recently bought and sold shares of the business. Mesirow Institutional Investment Management Inc. purchased a new stake in LeMaitre Vascular in the fourth quarter valued at $8,837,000. Congress Asset Management Co. MA boosted its stake in shares of LeMaitre Vascular by 36.3% in the third quarter. Congress Asset Management Co. MA now owns 508,379 shares of the medical instruments supplier’s stock worth $27,696,000 after buying an additional 135,266 shares during the last quarter. Ranger Investment Management L.P. grew its holdings in LeMaitre Vascular by 15.8% during the third quarter. Ranger Investment Management L.P. now owns 898,822 shares of the medical instruments supplier’s stock worth $48,968,000 after acquiring an additional 122,601 shares during the period. Summit Creek Advisors LLC raised its position in LeMaitre Vascular by 37.8% during the fourth quarter. Summit Creek Advisors LLC now owns 228,501 shares of the medical instruments supplier’s stock valued at $12,970,000 after acquiring an additional 62,737 shares in the last quarter. Finally, Conestoga Capital Advisors LLC raised its position in LeMaitre Vascular by 3.0% during the third quarter. Conestoga Capital Advisors LLC now owns 1,917,581 shares of the medical instruments supplier’s stock valued at $104,470,000 after acquiring an additional 55,895 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have commented on LMAT shares. JMP Securities increased their price objective on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a research report on Friday, May 3rd. Barrington Research raised their price objective on LeMaitre Vascular from $69.00 to $79.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. StockNews.com upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. KeyCorp began coverage on shares of LeMaitre Vascular in a research report on Tuesday, February 6th. They set a “sector weight” rating on the stock. Finally, Stifel Nicolaus raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and increased their price objective for the stock from $59.00 to $75.00 in a research report on Friday, April 26th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and an average target price of $73.83.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.